Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 902 results for "Novartis Company"

Research and Markets: Chronic Plaque Psoriasis - Pipeline Review, H1 2014
Scottrade

Global Nicotine Gum Market 2014-2018: Key Vendors are GlaxoSmi...

Company News: Page (1) of 1 - 07/25/14 print page (July 25, 2014) DUBLIN , July 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Nicotine Gum Market 2014-2018" report to their offering. ... Review Seeker, 6 days ago
[x]  

145 images for Novartis Company

KansasCity.com, 2 weeks ago
Miami Herald, 2 weeks ago
International Business Times UK, 2 weeks ago
Irish Times, 2 weeks ago
Designboom, 2 weeks ago
Designboom, 2 weeks ago
Investing.com, 1 week ago
TopNews United States, 2 weeks ago
Sunday Post, 2 weeks ago
MassDevice, 2 weeks ago
FiercePharma

UPDATE 1-Novartis apologises for not disclosing side-effects of leukaemia drugs sooner

11:17am BST (Updates with company statement) TOKYO, July 31 (Reuters) - The Japanese unit of Novartis AG apologised on Thursday for nfailing to report to authorities in a timely manner side-effects of its leukaemia drugs, in the company's latest ...
 Reuters UK5 hours ago Novartis deeply regrets not reporting serious side effects of leukemia treatments sooner  MedCity News2 hours ago Novartis apologises for hiding side-effects of leukaemia drugs  Economic Times5 hours ago Novartis apologizes for lax business practices in Japan as side-effects scandal widens  FiercePharma1 hour ago
[x]  
MedCity News

Novartis - FDA accepts Sandoz application for biosimilar filgrastim

Release date- 23072014 - Holzkirchen - Sandoz, a Novartis Group company, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar pathway ...
 Pharmacy Choice1 week ago FDA accepts first biosimilar application under new approval pathway  Lexology10 hours ago Novartis To Offer Stiff Competition To Amgen's Neupogen  Bidness Etc6 days ago FDA paves way for Novartis to market biosimilar of Amgen's Neupogen in U.S.  MedCity News1 week ago
[x]  

Pfizer net earnings dips by 79% in Q2 to $2,912 million

Pfizer Inc, a second largest pharmaceutical company in the world after Novartis, has suffered heavy setback during the second quarter ended June 2014 on account of one time income received from sell of animal health business, Zoetis Inc., for a ...
 PharmaBiz1 day ago
MSN India

Novartis India Q1 net up 3 per cent at Rs. 14.31 crore

Standalone net sales of the company declined to Rs. 202.06 crore for the quarter under review Reuters New Delhi: Drug firm Novartis India on Friday reported a 3.17 per cent rise in standalone net profit at Rs. 14.31 crore for the quarter ended June 30, 2014.
 MSN India6 days ago Novartis India Q1 net up 3 pc at Rs 14.31 cr  Business Standard6 days ago Novartis India net sales plunge by 8% in Q1  PharmaBiz6 days ago Novartis India standalone quarterly net climbs 3.17%  MyIris4 days ago
[x]  

Novartis India: Outcome of AGM

Novartis India has informed that the Annual General Meeting (AGM) of the Company was held on July 25, 2014.
 Money Control6 days ago Novartis India's AGM on July 25, 2014  Money Control4 weeks ago Novartis India fixes book closure for dividend AGM  Money Control2 months ago
Motley Fool

Novartis India: Board recommends dividend

Novartis India has informed that the Board of Directors of the Company at its meeting held on May 22, 2014, has considered and approved the following: 1. Dividend recommendation of Rs. 10/- per equity share of Rs. 5/- each for the year ended March 31, 2014.
 Money Control2 months ago 5 Novartis Drugs You Need To Know About  Motley Fool1 week ago Novartis India to consider dividend on May 22, 2014  Money Control2 months ago
Business Standard

Ranbaxy receives first-to-file USFDA approval for valsartan

The company will launch valsartan tablets, which is the first generic version of Swiss drugmaker Novartis' Diovan, with 180-days marketing exclusivity BS B2B Bureau | Gurgaon June 27, 2014 Last Updated at 15:34 IST Ohm Laboratories Inc, a wholly owned ...
 Business Standard1 month ago Roche, Novartis protest moves in EU to pay for off-label Avastin  FiercePharma3 days ago Ranbaxy gets FDA approval for Novartis's Diovan generic  The Financial Chronicle1 month ago Ranbaxy jumps on buzz USFDA OKs generic drug  Business Standard1 month ago
[x]  

Novartis steps up innovation with key focus on oncology

The key takeaway was that the company is looking at a unique approach of using single target for multiple indications, one drug that can treat multiple indications.
 Money Control1 month ago

MNC drug companies like Roche, Merck Serono, Novartis see top deck reshuffle

These companies not only had to battle slow growth but also the fickle stand of Indian government over issues of intellectual property and a restriction on mergers. Roche and BMS were kept on their toes, with the sword of compulsory licence dangling over ...
 Economic Times1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less